Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort
Pla, Helena (Universitat de Girona)
Felip, Eudald (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Obadia, Verónica (Institut d'Investigació Biomèdica de Bellvitge)
Pernas, Sónia (Institut d'Investigació Biomèdica de Bellvitge)
Viñas, Gemma (Universitat de Girona)
Margelí, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Fort-Culillas, Roser (Universitat de Girona)
Del Barco, Sónia (Universitat de Girona)
Sabaté, Núria (Hospital Universitari de Girona Doctor Josep Trueta)
Fort, Eduard (Institut Català d'Oncologia)
Lezcano, Clara (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Cirauqui, Beatriz (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Quiroga García, Vanesa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Stradella, Agostina (Institut d'Investigació Biomèdica de Bellvitge)
Gil Gil, Miguel (Institut d'Investigació Biomèdica de Bellvitge)
Esteve, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Recalde, S. (Institut d'Investigació Biomèdica de Bellvitge)

Data:	2024
Resum:	Introduction: Cyclin-dependent kinases 4/6 inhibitors (CDK 4/6i) combined with endocrine therapy have become the gold standard in hormone receptor-positive (HR +) HER2-negative (HER2-) metastatic breast cancer (MBC). However, there is a significant lack of data regarding the efficacy and safety of these treatments in elderly patients. We present the results of a real-world data (RWD) cohort stratified by age at treatment initiation (≥ 70 years compared to patients < 70 years). Methods: Clinico-pathological data of HR + HER2- MBC patients who were candidates for CDK4/6i therapy between January 2017 and December 2020 at the Institut Català d'Oncologia (Spain) were retrospectively collected. The primary goal was to assess Progression-Free Survival (PFS), Overall Survival (OS), and safety outcomes within this patient population. Results: A total of 274 patients with MBC who received CDK4/6i treatment were included in the study. Among them, 84 patients (30. 8%) were aged ≥ 70 years, with a mean age of 75, while 190 patients (69. 2%) were under the age of 70, with a mean age of 55. 7 years. The most frequently observed grade 3-4 toxicity was neutropenia, with similar rates in both the < 70 group (43. 9%) and the ≥ 70 group (47. 9%) (p = 0. 728). The median Progression-Free Survival (mPFS) for the first-line CDK4/6i treatment was 22 months (95% CI, 15. 4-39. 8) in the < 70 group and 20. 8 months (95% CI 11. 2-NR) in the ≥ 70 group (p = 0. 67). Similarly, the median PFS for the second-line CDK4/6i treatment was 10. 4 months (95% CI, 7. 4-15. 1) and 7. 1 months (95% CI 4. 4-21. 3) (p = 0. 79), respectively. Median overall survival (mOS) was not reached either for the first- and second-line treatment. Conclusions: Our RWD suggests that elderly patients, when compared to those under 70, experience similar survival outcomes and exhibit comparable tolerance for CDK4/6i therapy.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Elderly population ; Real world ; Metastatic breast cancer ; CDK4/6 inhibitors ; Toxicity
Publicat a:	Clinical & translational oncology, Vol. 26 Núm. 7 (july 2024) , p. 1748-1758, ISSN 1699-3055

DOI: 10.1007/s12094-024-03399-3
PMID: 38519708

11 p, 2.6 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats